LT4234B - Compositions for treating mast-cell inflamatory condition - Google Patents

Compositions for treating mast-cell inflamatory condition Download PDF

Info

Publication number
LT4234B
LT4234B LT97-065A LT97065A LT4234B LT 4234 B LT4234 B LT 4234B LT 97065 A LT97065 A LT 97065A LT 4234 B LT4234 B LT 4234B
Authority
LT
Lithuania
Prior art keywords
cis
piperazinecarboxylate
bis
compound
cyclooctylene
Prior art date
Application number
LT97-065A
Other languages
English (en)
Lithuanian (lt)
Other versions
LT97065A (en
Inventor
Ken D Rice
Jeffrey M Dener
Anthony R Gangloff
Elaine Yee-Lin Kuo
Original Assignee
Arris Pharm Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arris Pharm Corp filed Critical Arris Pharm Corp
Publication of LT97065A publication Critical patent/LT97065A/xx
Publication of LT4234B publication Critical patent/LT4234B/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/215—Radicals derived from nitrogen analogues of carbonic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/32—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C271/34—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of rings other than six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/18—Systems containing only non-condensed rings with a ring being at least seven-membered

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
LT97-065A 1994-09-23 1997-04-10 Compositions for treating mast-cell inflamatory condition LT4234B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US31226994A 1994-09-23 1994-09-23

Publications (2)

Publication Number Publication Date
LT97065A LT97065A (en) 1997-08-25
LT4234B true LT4234B (en) 1997-10-27

Family

ID=23210670

Family Applications (1)

Application Number Title Priority Date Filing Date
LT97-065A LT4234B (en) 1994-09-23 1997-04-10 Compositions for treating mast-cell inflamatory condition

Country Status (25)

Country Link
US (2) US6022969A (fr)
EP (1) EP0782571A1 (fr)
JP (1) JPH10506390A (fr)
KR (1) KR970706267A (fr)
CN (1) CN1160398A (fr)
AU (1) AU694275B2 (fr)
CA (1) CA2200561A1 (fr)
CZ (1) CZ87097A3 (fr)
EE (1) EE03525B1 (fr)
FI (1) FI971171A (fr)
HR (1) HRP950499B1 (fr)
HU (1) HUT77770A (fr)
IL (1) IL115405A (fr)
LT (1) LT4234B (fr)
LV (1) LV11865B (fr)
MX (1) MX9702125A (fr)
NO (1) NO309605B1 (fr)
NZ (1) NZ294392A (fr)
PL (1) PL183552B1 (fr)
RU (1) RU2159229C2 (fr)
SI (1) SI9520101A (fr)
SK (1) SK37997A3 (fr)
TW (1) TW442478B (fr)
WO (1) WO1996009297A1 (fr)
ZA (1) ZA958028B (fr)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ29799A3 (cs) * 1996-07-30 1999-06-16 Arris Pharmaceutical Corporation Disubstituovaná cyklická sloučenina, způsob její výroby, farmaceutický přípravek a způsob léčení onemocnění živočicha
WO1998024886A1 (fr) * 1996-12-04 1998-06-11 Brigham And Women's Hospital, Inc. Protease issue de mastocytes clivant le fibrogene
US5955431A (en) * 1997-02-05 1999-09-21 Brigham And Women's Hospital, Inc. Mast cell protease peptide inhibitors
WO1999012918A1 (fr) * 1997-09-05 1999-03-18 Yoshitomi Pharmaceutical Industries, Ltd. Inhibiteur de la tryptase
US6221914B1 (en) 1997-11-10 2001-04-24 Array Biopharma Inc. Sulfonamide bridging compounds that inhibit tryptase activity
EP1030844A1 (fr) * 1997-11-10 2000-08-30 Array Biopharma Inc. Composes inhibant l'activite de la tryptase
EP1060171A2 (fr) * 1998-02-06 2000-12-20 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibiteurs de la tryptase
ES2233025T3 (es) 1998-02-06 2005-06-01 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Agente inhibidores de la triptasa.
AU5625499A (en) * 1998-09-04 2000-03-27 Altana Pharma Ag Novel pyranoses
US6362216B1 (en) 1998-10-27 2002-03-26 Array Biopharma Inc. Compounds which inhibit tryptase activity
WO2000051624A2 (fr) * 1999-03-05 2000-09-08 The Trustees Of University Technology Corporation Methodes et compositions utiles a l'inhibition de l'apoptose
US6849605B1 (en) * 1999-03-05 2005-02-01 The Trustees Of University Technology Corporation Inhibitors of serine protease activity, methods and compositions for treatment of viral infections
DE60014932T2 (de) 1999-08-10 2005-10-13 Altana Pharma Ag Diazocindionderivate und ihre verwendung als tryptase inhibitoren
AU778965B2 (en) * 1999-09-14 2004-12-23 Altana Pharma Ag Tryptase inhibitors
GB9923710D0 (en) * 1999-10-08 1999-12-08 Proteus Molecular Design Chemical compounds
WO2001036386A1 (fr) * 1999-11-17 2001-05-25 Sumitomo Pharmaceuticals Co., Ltd. Traitement du diabete contenant un derive de dipiperazine
TR200402322T4 (tr) * 1999-12-20 2004-12-21 Altana Pharma Ag Triptaz inhibitörler
CA2392127A1 (fr) 1999-12-20 2001-06-28 Byk Gulden Lomberg Chemische Fabrik Gmbh Inhibiteurs de tryptase
WO2001052883A1 (fr) * 2000-01-20 2001-07-26 Amgen Inc. Inhibiteurs du recepteur-2 active par une protease (par-2) utilises comme nouveaux agents therapeutiques contre l'asthme
US20020045613A1 (en) * 2000-04-27 2002-04-18 Heinz Pauls 1-aroyl-piperidinyl benzamidines
DK1358182T3 (da) * 2001-01-31 2004-12-20 Altana Pharma Ag Diazocin-derivater og anvendelsen deraf som tryptase-inhibitorer
ATE349427T1 (de) 2001-02-21 2007-01-15 Altana Pharma Ag Tryptaseinhibitoren
CA2438711A1 (fr) 2001-02-21 2002-08-29 Altana Pharma Ag Inhibiteurs de la tryptase
US20040087792A1 (en) * 2001-03-15 2004-05-06 Thomas Martin Tryptase-inhibitors
WO2002074732A2 (fr) * 2001-03-15 2002-09-26 Altana Pharma Ag Inhibiteurs de la tryptase
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US6818787B2 (en) * 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7186855B2 (en) 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7232924B2 (en) * 2001-06-11 2007-06-19 Xenoport, Inc. Methods for synthesis of acyloxyalkyl derivatives of GABA analogs
ES2278928T3 (es) 2001-06-19 2007-08-16 Altana Pharma Ag Inhibidores de triptasa.
AU2002352382A1 (en) * 2001-12-13 2003-06-23 Kowa Company Ltd Use of protease-activated receptor-2 inhibitor in the manifacture of a medicament for treating delayed hypersensitivity
WO2003075853A2 (fr) 2002-03-08 2003-09-18 Bristol-Myers Squibb Company Derives cycliques servant de modulateurs de l'activite du recepteur de la chimiokine
TW200524849A (en) * 2003-07-02 2005-08-01 Hoffmann La Roche Hydroxyalkylamide derivatives
US20050255154A1 (en) * 2004-05-11 2005-11-17 Lena Pereswetoff-Morath Method and composition for treating rhinitis
TW200815351A (en) * 2006-05-02 2008-04-01 Astrazeneca Ab Novel compounds
TWI414527B (zh) * 2010-10-06 2013-11-11 Ind Tech Res Inst 異山梨糖醇衍生物及包含該衍生物之液晶顯示器
CN102453037B (zh) * 2010-10-25 2014-06-25 财团法人工业技术研究院 异山梨糖醇衍生物及包含该衍生物的液晶显示器

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR208414A1 (es) * 1974-11-07 1976-12-27 Rhone Poulenc Ind Procedimiento para obtener nuevos derivados de la((acil-4piperazinil-1)carboniloxi-5 pirrolinona-2)
US4746737A (en) * 1985-07-26 1988-05-24 Kowa Co., Ltd. Phenyl guanidinobenzoate derivatives which have protease inhibitory activity
JPH08507768A (ja) * 1993-03-12 1996-08-20 アリス ファーマシューティカル コーポレイション 免疫仲介炎症疾患の処置のための組成物および方法
US5525623A (en) * 1993-03-12 1996-06-11 Arris Pharmaceutical Corporation Compositions and methods for the treatment of immunomediated inflammatory disorders
JPH10501238A (ja) * 1994-06-01 1998-02-03 アリス ファーマシューティカル コーポレイション 肥満細胞媒介症状を治療するための組成物及び方法

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CAUGHEY GH ET AL.: "Substance P and vasoactive intestinal peptide degradation by mast cell tryptase and chymase", J. PHARMACOL. EXP. THER., 1988, pages 947 - 951
HOOD ET AL.: "Immunology"
PETER VANDERSLICE ET AL.: "Molecular cloning of dog mast cell tryptase and a related protease: structural evidence of a unique mode of serine protease activation", BIOCHEMISTRY, 1989, pages 4148 - 4155
VANDERSLICE, P. ET AL.: "Human mast cell tryptase: Multiple cDNAs and genes reveal a multigene serine protease", PROC NATL ACAD SCI U S A., 1990, pages 3811 - 3815, XP002092772, DOI: doi:10.1073/pnas.87.10.3811

Also Published As

Publication number Publication date
EE03525B1 (et) 2001-10-15
CN1160398A (zh) 1997-09-24
NO971305D0 (no) 1997-03-20
HRP950499B1 (en) 2003-04-30
EP0782571A1 (fr) 1997-07-09
LV11865A (lv) 1997-10-20
PL319587A1 (en) 1997-08-18
IL115405A0 (en) 1995-12-31
LT97065A (en) 1997-08-25
JPH10506390A (ja) 1998-06-23
KR970706267A (ko) 1997-11-03
TW442478B (en) 2001-06-23
NO309605B1 (no) 2001-02-26
CA2200561A1 (fr) 1996-03-28
ZA958028B (en) 1996-04-18
IL115405A (en) 2002-07-25
FI971171A0 (fi) 1997-03-20
PL183552B1 (pl) 2002-06-28
WO1996009297A1 (fr) 1996-03-28
LV11865B (en) 1998-01-20
EE9700089A (et) 1997-10-15
FI971171A (fi) 1997-03-20
SI9520101A (en) 1997-12-31
AU3718095A (en) 1996-04-09
NZ294392A (en) 1999-05-28
SK37997A3 (en) 1998-12-02
US6022969A (en) 2000-02-08
AU694275B2 (en) 1998-07-16
RU2159229C2 (ru) 2000-11-20
MX9702125A (es) 1998-04-30
NO971305L (no) 1997-05-06
HRP950499A2 (en) 1997-08-31
US6211228B1 (en) 2001-04-03
CZ87097A3 (en) 1997-11-12
HUT77770A (hu) 1998-08-28

Similar Documents

Publication Publication Date Title
LT4234B (en) Compositions for treating mast-cell inflamatory condition
EP0763016B1 (fr) Compositions et procedes de traitement d'etats induits par des mastocytes
JP2002502850A (ja) トリプターゼ阻害物質
ES2222259T3 (es) Inhibidores de triptasa.
ES2222270T3 (es) Inhibidores de triptasa.
CA2381919A1 (fr) Inhibiteurs de tryptase
EP1401809B1 (fr) Inhibiteurs de tryptase
EP1368317B1 (fr) Inhibiteurs de tryptase
AU2002253035A1 (en) Tryptase inhibitors
CA2438711A1 (fr) Inhibiteurs de la tryptase
JP2004525926A (ja) トリプターゼ阻害剤

Legal Events

Date Code Title Description
PD9A Change of patent owner

Free format text: AXYS PHARMACEUTICALS, INC,385 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA 94080,US,19991015

MM9A Lapsed patents

Effective date: 20030914